PMID: 9537682Apr 16, 1998Paper

Central nicotinic receptor agonists ABT-418, ABT-089, and (-)-nicotine reduce distractibility in adult monkeys

Psychopharmacology
M A PrendergastJerry J Buccafusco

Abstract

Increased distractibility is associated with both Alzheimer's disease and attention deficit disorder. The present study examined the effects of (-)-nicotine and the novel central nicotinic receptor (nAChR) agonists ABT-418 [(S)-3-methyl-2-pyrrolidinyl)isoxazole] and ABT-089 [2-methyl-3-(2-(S)-pyrrolindinylmethoxy)pyridine dihydrochloride] on the delayed recall accuracy of adult monkeys exposed to distracting stimuli. Unpredictable exposure to a random visual array produced marked decrements in recall accuracy on trials with the shortest delay intervals, reducing the accuracy on these trials by 23.4%. Intramuscular (i.m.) administration of (-)-nicotine, in doses of 5.4-43.3 nmol/kg, attenuated the effect of the distractor, but did not completely prevent it. Both ABT-418 (2.0-16.2 nmol/kg, i.m.) and ABT-089 (16.4-32.8 nmol/kg, i.m.) prevented distractibility, producing increases of 7.5-25.0% in accuracy on trials disrupted by distractor exposure. Further, both compounds also improved accuracy on trials during which distractors were not presented, an effect which was not observed after (-)-nicotine administration. Nicotinic-mediated side effects were not observed following administration of any compound. Thus, nAChR stimulation re...Continue Reading

Citations

Apr 28, 2004·Psychopharmacology·Simon N KatnerMichael A Taffe
Sep 6, 2002·Journal of Molecular Neuroscience : MN·Jerry J BuccafuscoPaul B Murdoch
Nov 1, 2003·Pharmacology, Biochemistry, and Behavior·Joseph O'NeillL Jaime Fitten
Mar 7, 2001·Biological Psychiatry·P A NewhouseJ Corwin
May 24, 2003·Neuropharmacology·Britta HahnIan P Stolerman
May 17, 2000·Pharmaceutica acta Helvetiae·P A Newhouse, M Kelton
Jul 6, 2000·Archives of Medical Research·S Mihailescu, R Drucker-Colín
Feb 12, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·William M HoweMartin Sarter
Oct 1, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Carrie K JonesMichael Bubser
Aug 8, 2002·Fundamental & Clinical Pharmacology·Roger D PorsoltSylvain Roux
Apr 20, 2010·Behavioural Pharmacology·Justin W KenneyThomas J Gould
Feb 1, 2007·Neuropsychiatric Disease and Treatment·Hervé AllainDanièle Bentué-Ferrer
Oct 15, 2013·Cellular and Molecular Life Sciences : CMLS·Eliane ProulxEvelyn K Lambe
Jun 27, 2014·Expert Opinion on Investigational Drugs·Carl Fleisher, James McGough
Feb 15, 2011·Pharmacology, Biochemistry, and Behavior·Alvin V TerryScott J Webster
Mar 23, 2007·European Journal of Pharmacology·Dariusz PogockiElzbieta Wałajtys-Rode
Aug 2, 2015·Biochemical Pharmacology·Alvin V TerryCaterina M Hernandez
Sep 26, 2006·Trends in Pharmacological Sciences·Martin Sarter
Mar 19, 2011·Biochemical Pharmacology·Stephen P Arneric, Michael Williams
Apr 24, 2015·Addiction Biology·Francis Joseph McClernonDana M Van Wert
Jul 5, 2005·Expert Opinion on Investigational Drugs·D Gurwitz
Jan 21, 2014·Behavioural Processes·John J ChelonisMerle G Paule
Jun 10, 2005·Neuron·Angela J Yu, Peter Dayan
Oct 12, 2014·Psychopharmacology·Oliver BehlerChristiane M Thiel
Nov 16, 2016·PLoS Biology·Louise MarshallSven Bestmann
Aug 24, 2018·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·Alvin V Terry, Patrick M Callahan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.